The underlying mechanism of pacritinib’s anemia benefits had not been elucidated until its inhibitory activity on the ACVR1/SMAD pathway and suppression of hepcidin expression were demonstrated in 2023 [29]. This evidence concerns the gene ACVR1 and anemia.